Healthcare provider profile · identity verified

Marshal Alan Blatt, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MONTEREY, CA · NPI 1699882423

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Marshal Alan Blatt, M.D. received $6,561.77 in general payments during 2025 across 451 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 15.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 20 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Caplyta, Rexulti, Trintellix, Uzedy, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Spravato by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify Maintena by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Uzedy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$6,561.77

451 reported records · 15 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$1,021.58	15.6%	89	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$1,011.29	15.4%	69	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$982.84	15.0%	58	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$672.42	10.2%	56	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$495.55	7.5%	40	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$472.22	7.2%	23	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$467.53	7.1%	35	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$395.29	6.0%	19	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$365.81	5.6%	15	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$310.07	4.7%	24	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$156.26	2.4%	8	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$146.03	2.2%	11	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$30.41	0.5%	2	2025
IDORSIA PHARMACEUTICALS US INC	Unresolved — no canonical attribution shown	$20.08	0.3%	1	2025
Biogen, Inc.	Unresolved — no canonical attribution shown	$14.39	0.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$6,361.83	449
Education	$199.94	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$1,021.58	89	2025
Source payment records 2025-01-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.63 · Open Payments source 2025-01-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.29 · Open Payments source 2025-01-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $0.74 · Open Payments source 2025-01-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.29 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.88 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.17 · Open Payments source 2025-02-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.02 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.60 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.30 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.87 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.27 · Open Payments source 2025-03-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.16 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.86 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.14 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.12 · Open Payments source 2025-04-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.55 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.33 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.17 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.16 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.38 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.75 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.91 · Open Payments source 2025-04-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.87 · Open Payments source 2025-05-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.33 · Open Payments source 2025-05-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.89 · Open Payments source 2025-05-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.33 · Open Payments source 2025-05-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.49 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.53 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.00 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.14 · Open Payments source 2025-06-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.30 · Open Payments source 2025-06-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.34 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.65 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.28 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.66 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.57 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.35 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.75 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.53 · Open Payments source 2025-07-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.71 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.63 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.70 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $0.56 · Open Payments source 2025-07-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.20 · Open Payments source 2025-07-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.62 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.10 · Open Payments source 2025-08-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.73 · Open Payments source 2025-08-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.48 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.44 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.73 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.77 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.03 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.33 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.94 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.10 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.55 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.81 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.79 · Open Payments source 2025-10-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.66 · Open Payments source 2025-10-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $0.66 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.98 · Open Payments source 2025-10-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.09 · Open Payments source 2025-10-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.07 · Open Payments source 2025-10-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.22 · Open Payments source 2025-10-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.45 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.04 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.53 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.60 · Open Payments source 2025-11-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.24 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.70 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.58 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.96 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.60 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.16 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.27 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.65 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.69 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.50 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.93 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.49 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.46 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.15 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.96 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.72 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.03 · Open Payments source 2025-12-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.91 · Open Payments source 2025-12-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.96 · Open Payments source 2025-12-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.50 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$982.84	58	2025
Source payment records 2025-01-16 · Neurocrine BioSciences, Inc. · $18.21 · Open Payments source 2025-01-16 · Neurocrine BioSciences, Inc. · $9.86 · Open Payments source 2025-01-29 · Neurocrine BioSciences, Inc. · $37.85 · Open Payments source 2025-02-12 · Neurocrine BioSciences, Inc. · $27.55 · Open Payments source 2025-02-13 · Neurocrine BioSciences, Inc. · $7.36 · Open Payments source 2025-02-20 · Neurocrine BioSciences, Inc. · $29.66 · Open Payments source 2025-03-14 · Neurocrine BioSciences, Inc. · $6.92 · Open Payments source 2025-03-15 · Neurocrine BioSciences, Inc. · $17.76 · Open Payments source 2025-03-26 · Neurocrine BioSciences, Inc. · $28.80 · Open Payments source 2025-04-03 · Neurocrine BioSciences, Inc. · $24.93 · Open Payments source 2025-04-09 · Neurocrine BioSciences, Inc. · $26.43 · Open Payments source 2025-04-09 · Neurocrine BioSciences, Inc. · $1.37 · Open Payments source 2025-04-22 · Neurocrine BioSciences, Inc. · $9.91 · Open Payments source 2025-04-22 · Neurocrine BioSciences, Inc. · $8.44 · Open Payments source 2025-05-10 · Neurocrine BioSciences, Inc. · $24.83 · Open Payments source 2025-05-10 · Neurocrine BioSciences, Inc. · $4.84 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $34.76 · Open Payments source 2025-05-21 · Neurocrine BioSciences, Inc. · $4.56 · Open Payments source 2025-05-21 · Neurocrine BioSciences, Inc. · $2.87 · Open Payments source 2025-05-22 · Neurocrine BioSciences, Inc. · $26.67 · Open Payments source 2025-05-22 · Neurocrine BioSciences, Inc. · $15.07 · Open Payments source 2025-05-22 · Neurocrine BioSciences, Inc. · $11.60 · Open Payments source 2025-06-04 · Neurocrine BioSciences, Inc. · $18.52 · Open Payments source 2025-06-05 · Neurocrine BioSciences, Inc. · $13.40 · Open Payments source 2025-06-11 · Neurocrine BioSciences, Inc. · $22.22 · Open Payments source 2025-06-12 · Neurocrine BioSciences, Inc. · $11.10 · Open Payments source 2025-06-20 · Neurocrine BioSciences, Inc. · $13.82 · Open Payments source 2025-07-17 · Neurocrine BioSciences, Inc. · $33.11 · Open Payments source 2025-07-25 · Neurocrine BioSciences, Inc. · $19.64 · Open Payments source 2025-07-26 · Neurocrine BioSciences, Inc. · $11.55 · Open Payments source 2025-08-02 · Neurocrine BioSciences, Inc. · $19.15 · Open Payments source 2025-08-02 · Neurocrine BioSciences, Inc. · $10.64 · Open Payments source 2025-08-06 · Neurocrine BioSciences, Inc. · $10.03 · Open Payments source 2025-08-07 · Neurocrine BioSciences, Inc. · $14.57 · Open Payments source 2025-08-14 · Neurocrine BioSciences, Inc. · $28.17 · Open Payments source 2025-09-04 · Neurocrine BioSciences, Inc. · $23.10 · Open Payments source 2025-09-04 · Neurocrine BioSciences, Inc. · $8.59 · Open Payments source 2025-09-24 · Neurocrine BioSciences, Inc. · $29.12 · Open Payments source 2025-10-08 · Neurocrine BioSciences, Inc. · $31.32 · Open Payments source 2025-10-09 · Neurocrine BioSciences, Inc. · $4.27 · Open Payments source 2025-10-15 · Neurocrine BioSciences, Inc. · $17.31 · Open Payments source 2025-10-15 · Neurocrine BioSciences, Inc. · $5.28 · Open Payments source 2025-10-22 · Neurocrine BioSciences, Inc. · $26.31 · Open Payments source 2025-10-22 · Neurocrine BioSciences, Inc. · $3.12 · Open Payments source 2025-10-29 · Neurocrine BioSciences, Inc. · $8.91 · Open Payments source 2025-10-30 · Neurocrine BioSciences, Inc. · $20.66 · Open Payments source 2025-11-06 · Neurocrine BioSciences, Inc. · $10.69 · Open Payments source 2025-11-07 · Neurocrine BioSciences, Inc. · $16.30 · Open Payments source 2025-11-11 · Neurocrine BioSciences, Inc. · $22.94 · Open Payments source 2025-11-12 · Neurocrine BioSciences, Inc. · $8.59 · Open Payments source 2025-11-13 · Neurocrine BioSciences, Inc. · $23.41 · Open Payments source 2025-11-19 · Neurocrine BioSciences, Inc. · $27.85 · Open Payments source 2025-11-19 · Neurocrine BioSciences, Inc. · $7.82 · Open Payments source 2025-12-04 · Neurocrine BioSciences, Inc. · $5.70 · Open Payments source 2025-12-10 · Neurocrine BioSciences, Inc. · $26.73 · Open Payments source 2025-12-17 · Neurocrine BioSciences, Inc. · $18.70 · Open Payments source 2025-12-17 · Neurocrine BioSciences, Inc. · $10.02 · Open Payments source 2025-12-22 · Neurocrine BioSciences, Inc. · $19.93 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$852.72	62	2025
Source payment records 2025-01-04 · Axsome Therapeutics, Inc. · $6.13 · Open Payments source 2025-01-04 · Axsome Therapeutics, Inc. · $26.21 · Open Payments source 2025-01-11 · Axsome Therapeutics, Inc. · $21.86 · Open Payments source 2025-01-15 · Axsome Therapeutics, Inc. · $25.16 · Open Payments source 2025-01-27 · Axsome Therapeutics, Inc. · $6.08 · Open Payments source 2025-01-28 · Axsome Therapeutics, Inc. · $24.40 · Open Payments source 2025-02-03 · Axsome Therapeutics, Inc. · $3.57 · Open Payments source 2025-02-04 · Axsome Therapeutics, Inc. · $11.89 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $3.26 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $10.70 · Open Payments source 2025-02-22 · Axsome Therapeutics, Inc. · $5.21 · Open Payments source 2025-02-22 · Axsome Therapeutics, Inc. · $16.67 · Open Payments source 2025-03-12 · Axsome Therapeutics, Inc. · $19.09 · Open Payments source 2025-03-21 · Axsome Therapeutics, Inc. · $25.65 · Open Payments source 2025-03-21 · Axsome Therapeutics, Inc. · $5.59 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $18.94 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $5.83 · Open Payments source 2025-04-05 · Axsome Therapeutics, Inc. · $7.00 · Open Payments source 2025-04-05 · Axsome Therapeutics, Inc. · $13.78 · Open Payments source 2025-04-05 · Axsome Therapeutics, Inc. · $2.37 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $6.63 · Open Payments source 2025-04-12 · Axsome Therapeutics, Inc. · $6.94 · Open Payments source 2025-04-22 · Axsome Therapeutics, Inc. · $20.69 · Open Payments source 2025-04-22 · Axsome Therapeutics, Inc. · $4.35 · Open Payments source 2025-05-02 · Axsome Therapeutics, Inc. · $4.97 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $26.54 · Open Payments source 2025-05-16 · Axsome Therapeutics, Inc. · $12.38 · Open Payments source 2025-05-17 · Axsome Therapeutics, Inc. · $2.78 · Open Payments source 2025-05-31 · Axsome Therapeutics, Inc. · $11.12 · Open Payments source 2025-05-31 · Axsome Therapeutics, Inc. · $11.31 · Open Payments source 2025-06-10 · Axsome Therapeutics, Inc. · $21.62 · Open Payments source 2025-06-10 · Axsome Therapeutics, Inc. · $5.54 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $8.87 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $23.91 · Open Payments source 2025-06-26 · Axsome Therapeutics, Inc. · $22.63 · Open Payments source 2025-06-26 · Axsome Therapeutics, Inc. · $2.58 · Open Payments source 2025-06-28 · Axsome Therapeutics, Inc. · $21.56 · Open Payments source 2025-06-28 · Axsome Therapeutics, Inc. · $7.88 · Open Payments source 2025-07-04 · Axsome Therapeutics, Inc. · $17.61 · Open Payments source 2025-07-04 · Axsome Therapeutics, Inc. · $9.35 · Open Payments source 2025-07-12 · Axsome Therapeutics, Inc. · $29.07 · Open Payments source 2025-07-30 · Axsome Therapeutics, Inc. · $15.60 · Open Payments source 2025-07-30 · Axsome Therapeutics, Inc. · $7.64 · Open Payments source 2025-08-09 · Axsome Therapeutics, Inc. · $33.27 · Open Payments source 2025-08-19 · Axsome Therapeutics, Inc. · $7.26 · Open Payments source 2025-08-19 · Axsome Therapeutics, Inc. · $17.64 · Open Payments source 2025-08-26 · Axsome Therapeutics, Inc. · $7.79 · Open Payments source 2025-08-26 · Axsome Therapeutics, Inc. · $22.12 · Open Payments source 2025-10-08 · Axsome Therapeutics, Inc. · $2.16 · Open Payments source 2025-10-08 · Axsome Therapeutics, Inc. · $15.41 · Open Payments source 2025-10-08 · Axsome Therapeutics, Inc. · $15.65 · Open Payments source 2025-10-18 · Axsome Therapeutics, Inc. · $31.66 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $20.14 · Open Payments source 2025-11-14 · Axsome Therapeutics, Inc. · $3.58 · Open Payments source 2025-11-15 · Axsome Therapeutics, Inc. · $11.43 · Open Payments source 2025-11-15 · Axsome Therapeutics, Inc. · $12.11 · Open Payments source 2025-11-22 · Axsome Therapeutics, Inc. · $23.75 · Open Payments source 2025-11-22 · Axsome Therapeutics, Inc. · $8.67 · Open Payments source 2025-12-05 · Axsome Therapeutics, Inc. · $14.43 · Open Payments source 2025-12-06 · Axsome Therapeutics, Inc. · $14.71 · Open Payments source 2025-12-13 · Axsome Therapeutics, Inc. · $23.04 · Open Payments source 2025-12-13 · Axsome Therapeutics, Inc. · $6.94 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$755.26	47	2025
Source payment records 2025-01-06 · Lundbeck LLC · $30.90 · Open Payments source 2025-01-13 · Otsuka America Pharmaceutical, Inc. · $3.79 · Open Payments source 2025-01-14 · Otsuka America Pharmaceutical, Inc. · $25.90 · Open Payments source 2025-01-28 · Lundbeck LLC · $26.63 · Open Payments source 2025-02-03 · Otsuka America Pharmaceutical, Inc. · $18.55 · Open Payments source 2025-02-03 · Otsuka America Pharmaceutical, Inc. · $4.61 · Open Payments source 2025-02-19 · Otsuka America Pharmaceutical, Inc. · $28.95 · Open Payments source 2025-02-26 · Lundbeck LLC · $23.49 · Open Payments source 2025-03-19 · Lundbeck LLC · $19.66 · Open Payments source 2025-03-26 · Otsuka America Pharmaceutical, Inc. · $5.83 · Open Payments source 2025-03-26 · Otsuka America Pharmaceutical, Inc. · $11.97 · Open Payments source 2025-03-26 · Otsuka America Pharmaceutical, Inc. · $6.73 · Open Payments source 2025-03-26 · Otsuka America Pharmaceutical, Inc. · $4.89 · Open Payments source 2025-04-01 · Lundbeck LLC · $28.35 · Open Payments source 2025-04-23 · Lundbeck LLC · $18.91 · Open Payments source 2025-04-23 · Lundbeck LLC · $5.75 · Open Payments source 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $4.30 · Open Payments source 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $23.86 · Open Payments source 2025-05-19 · Lundbeck LLC · $19.33 · Open Payments source 2025-06-11 · Lundbeck LLC · $22.72 · Open Payments source 2025-06-16 · Lundbeck LLC · $22.70 · Open Payments source 2025-07-02 · Lundbeck LLC · $13.66 · Open Payments source 2025-07-23 · Lundbeck LLC · $16.96 · Open Payments source 2025-07-23 · Lundbeck LLC · $28.95 · Open Payments source 2025-07-28 · Otsuka America Pharmaceutical, Inc. · $1.49 · Open Payments source 2025-07-28 · Otsuka America Pharmaceutical, Inc. · $13.32 · Open Payments source 2025-07-28 · Otsuka America Pharmaceutical, Inc. · $11.37 · Open Payments source 2025-08-06 · Lundbeck LLC · $10.38 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $24.08 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $5.77 · Open Payments source 2025-09-03 · Lundbeck LLC · $16.02 · Open Payments source 2025-09-04 · Otsuka America Pharmaceutical, Inc. · $17.72 · Open Payments source 2025-09-04 · Otsuka America Pharmaceutical, Inc. · $11.40 · Open Payments source 2025-09-23 · Otsuka America Pharmaceutical, Inc. · $25.23 · Open Payments source 2025-09-30 · Lundbeck LLC · $23.49 · Open Payments source 2025-10-10 · Lundbeck LLC · $29.74 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $22.10 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $6.73 · Open Payments source 2025-10-20 · Lundbeck LLC · $28.04 · Open Payments source 2025-10-21 · Lundbeck LLC · $9.61 · Open Payments source 2025-10-23 · Otsuka America Pharmaceutical, Inc. · $1.17 · Open Payments source 2025-10-24 · Otsuka America Pharmaceutical, Inc. · $21.90 · Open Payments source 2025-11-18 · Otsuka America Pharmaceutical, Inc. · $28.35 · Open Payments source 2025-11-18 · Otsuka America Pharmaceutical, Inc. · $4.21 · Open Payments source 2025-12-09 · Otsuka America Pharmaceutical, Inc. · $4.15 · Open Payments source 2025-12-09 · Otsuka America Pharmaceutical, Inc. · $13.23 · Open Payments source 2025-12-09 · Otsuka America Pharmaceutical, Inc. · $8.37 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$672.42	56	2025
Source payment records 2025-01-06 · ABBVIE INC. · $18.89 · Open Payments source 2025-01-15 · ABBVIE INC. · $12.02 · Open Payments source 2025-01-18 · ABBVIE INC. · $20.45 · Open Payments source 2025-01-31 · ABBVIE INC. · $16.10 · Open Payments source 2025-02-08 · ABBVIE INC. · $29.36 · Open Payments source 2025-02-17 · ABBVIE INC. · $11.12 · Open Payments source 2025-02-26 · ABBVIE INC. · $2.10 · Open Payments source 2025-03-03 · ABBVIE INC. · $22.62 · Open Payments source 2025-03-10 · ABBVIE INC. · $4.81 · Open Payments source 2025-03-11 · ABBVIE INC. · $4.17 · Open Payments source 2025-03-24 · ABBVIE INC. · $12.74 · Open Payments source 2025-03-26 · ABBVIE INC. · $9.67 · Open Payments source 2025-04-07 · ABBVIE INC. · $18.42 · Open Payments source 2025-04-14 · ABBVIE INC. · $14.67 · Open Payments source 2025-04-21 · ABBVIE INC. · $3.31 · Open Payments source 2025-05-05 · ABBVIE INC. · $22.42 · Open Payments source 2025-05-06 · ABBVIE INC. · $6.69 · Open Payments source 2025-05-12 · ABBVIE INC. · $13.42 · Open Payments source 2025-05-19 · ABBVIE INC. · $20.98 · Open Payments source 2025-05-19 · ABBVIE INC. · $1.97 · Open Payments source 2025-05-21 · ABBVIE INC. · $6.37 · Open Payments source 2025-06-02 · ABBVIE INC. · $12.07 · Open Payments source 2025-06-03 · ABBVIE INC. · $9.09 · Open Payments source 2025-06-15 · ABBVIE INC. · $17.82 · Open Payments source 2025-06-18 · ABBVIE INC. · $8.36 · Open Payments source 2025-07-07 · ABBVIE INC. · $9.70 · Open Payments source 2025-07-21 · ABBVIE INC. · $9.08 · Open Payments source 2025-07-23 · ABBVIE INC. · $7.30 · Open Payments source 2025-07-28 · ABBVIE INC. · $5.57 · Open Payments source 2025-07-30 · ABBVIE INC. · $2.88 · Open Payments source 2025-08-04 · ABBVIE INC. · $18.02 · Open Payments source 2025-08-13 · ABBVIE INC. · $29.47 · Open Payments source 2025-08-13 · ABBVIE INC. · $4.35 · Open Payments source 2025-08-18 · ABBVIE INC. · $9.68 · Open Payments source 2025-08-26 · ABBVIE INC. · $2.63 · Open Payments source 2025-09-02 · ABBVIE INC. · $20.52 · Open Payments source 2025-09-04 · ABBVIE INC. · $30.26 · Open Payments source 2025-09-05 · ABBVIE INC. · $24.92 · Open Payments source 2025-09-13 · ABBVIE INC. · $12.04 · Open Payments source 2025-09-18 · ABBVIE INC. · $8.62 · Open Payments source 2025-09-24 · ABBVIE INC. · $9.72 · Open Payments source 2025-10-01 · ABBVIE INC. · $17.21 · Open Payments source 2025-10-08 · ABBVIE INC. · $2.88 · Open Payments source 2025-10-13 · ABBVIE INC. · $12.27 · Open Payments source 2025-10-14 · ABBVIE INC. · $7.40 · Open Payments source 2025-10-22 · ABBVIE INC. · $2.88 · Open Payments source 2025-10-29 · ABBVIE INC. · $7.40 · Open Payments source 2025-11-05 · ABBVIE INC. · $7.40 · Open Payments source 2025-11-10 · ABBVIE INC. · $14.86 · Open Payments source 2025-11-17 · ABBVIE INC. · $9.84 · Open Payments source 2025-11-19 · ABBVIE INC. · $9.38 · Open Payments source 2025-12-01 · ABBVIE INC. · $10.79 · Open Payments source 2025-12-04 · ABBVIE INC. · $16.12 · Open Payments source 2025-12-09 · ABBVIE INC. · $12.90 · Open Payments source 2025-12-10 · ABBVIE INC. · $2.22 · Open Payments source 2025-12-17 · ABBVIE INC. · $14.47 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$467.53	35	2025
Source payment records 2025-01-08 · Vanda Pharmaceuticals Inc. · $14.83 · Open Payments source 2025-02-04 · Vanda Pharmaceuticals Inc. · $20.78 · Open Payments source 2025-02-27 · Vanda Pharmaceuticals Inc. · $0.56 · Open Payments source 2025-02-28 · Vanda Pharmaceuticals Inc. · $18.87 · Open Payments source 2025-02-28 · Vanda Pharmaceuticals Inc. · $1.29 · Open Payments source 2025-03-11 · Vanda Pharmaceuticals Inc. · $14.90 · Open Payments source 2025-03-26 · Vanda Pharmaceuticals Inc. · $17.47 · Open Payments source 2025-04-02 · Vanda Pharmaceuticals Inc. · $13.73 · Open Payments source 2025-04-17 · Vanda Pharmaceuticals Inc. · $32.67 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $19.69 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $10.57 · Open Payments source 2025-05-07 · Vanda Pharmaceuticals Inc. · $27.63 · Open Payments source 2025-05-29 · Vanda Pharmaceuticals Inc. · $9.86 · Open Payments source 2025-05-29 · Vanda Pharmaceuticals Inc. · $13.53 · Open Payments source 2025-06-13 · Vanda Pharmaceuticals Inc. · $5.59 · Open Payments source 2025-06-13 · Vanda Pharmaceuticals Inc. · $13.27 · Open Payments source 2025-06-25 · Vanda Pharmaceuticals Inc. · $13.95 · Open Payments source 2025-06-30 · Vanda Pharmaceuticals Inc. · $29.16 · Open Payments source 2025-07-14 · Vanda Pharmaceuticals Inc. · $11.45 · Open Payments source 2025-07-15 · Vanda Pharmaceuticals Inc. · $4.35 · Open Payments source 2025-07-23 · Vanda Pharmaceuticals Inc. · $26.80 · Open Payments source 2025-08-01 · Vanda Pharmaceuticals Inc. · $10.12 · Open Payments source 2025-08-01 · Vanda Pharmaceuticals Inc. · $1.66 · Open Payments source 2025-08-06 · Vanda Pharmaceuticals Inc. · $10.88 · Open Payments source 2025-09-09 · Vanda Pharmaceuticals Inc. · $7.80 · Open Payments source 2025-09-09 · Vanda Pharmaceuticals Inc. · $21.56 · Open Payments source 2025-10-06 · Vanda Pharmaceuticals Inc. · $21.89 · Open Payments source 2025-10-07 · Vanda Pharmaceuticals Inc. · $5.69 · Open Payments source 2025-10-27 · Vanda Pharmaceuticals Inc. · $8.16 · Open Payments source 2025-10-27 · Vanda Pharmaceuticals Inc. · $18.84 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $22.07 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $2.67 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $7.16 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $5.85 · Open Payments source 2025-12-04 · Vanda Pharmaceuticals Inc. · $2.23 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$365.81	15	2025
Source payment records 2025-01-09 · E.R. Squibb & Sons, L.L.C. · $15.65 · Open Payments source 2025-01-21 · E.R. Squibb & Sons, L.L.C. · $90.59 · Open Payments source 2025-02-06 · E.R. Squibb & Sons, L.L.C. · $15.15 · Open Payments source 2025-03-18 · E.R. Squibb & Sons, L.L.C. · $21.48 · Open Payments source 2025-04-01 · E.R. Squibb & Sons, L.L.C. · $26.63 · Open Payments source 2025-04-09 · E.R. Squibb & Sons, L.L.C. · $8.85 · Open Payments source 2025-05-12 · E.R. Squibb & Sons, L.L.C. · $24.92 · Open Payments source 2025-05-23 · E.R. Squibb & Sons, L.L.C. · $20.85 · Open Payments source 2025-06-04 · E.R. Squibb & Sons, L.L.C. · $10.73 · Open Payments source 2025-07-09 · E.R. Squibb & Sons, L.L.C. · $25.89 · Open Payments source 2025-07-21 · E.R. Squibb & Sons, L.L.C. · $24.19 · Open Payments source 2025-07-30 · E.R. Squibb & Sons, L.L.C. · $24.70 · Open Payments source 2025-09-12 · E.R. Squibb & Sons, L.L.C. · $19.11 · Open Payments source 2025-10-31 · E.R. Squibb & Sons, L.L.C. · $22.10 · Open Payments source 2025-12-11 · E.R. Squibb & Sons, L.L.C. · $14.97 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$310.07	24	2025
Source payment records 2025-01-06 · Alkermes, Inc. · $10.98 · Open Payments source 2025-01-22 · Alkermes, Inc. · $16.47 · Open Payments source 2025-02-21 · Alkermes, Inc. · $23.43 · Open Payments source 2025-03-12 · Alkermes, Inc. · $6.02 · Open Payments source 2025-03-12 · Alkermes, Inc. · $4.29 · Open Payments source 2025-04-17 · Alkermes, Inc. · $10.78 · Open Payments source 2025-04-28 · Alkermes, Inc. · $11.46 · Open Payments source 2025-05-05 · Alkermes, Inc. · $13.54 · Open Payments source 2025-05-19 · Alkermes, Inc. · $11.74 · Open Payments source 2025-05-29 · Alkermes, Inc. · $9.77 · Open Payments source 2025-06-11 · Alkermes, Inc. · $21.56 · Open Payments source 2025-06-18 · Alkermes, Inc. · $10.22 · Open Payments source 2025-06-21 · Alkermes, Inc. · $7.19 · Open Payments source 2025-07-10 · Alkermes, Inc. · $20.44 · Open Payments source 2025-07-23 · Alkermes, Inc. · $20.44 · Open Payments source 2025-08-04 · Alkermes, Inc. · $10.78 · Open Payments source 2025-09-03 · Alkermes, Inc. · $10.78 · Open Payments source 2025-09-12 · Alkermes, Inc. · $10.78 · Open Payments source 2025-10-01 · Alkermes, Inc. · $11.95 · Open Payments source 2025-10-07 · Alkermes, Inc. · $10.40 · Open Payments source 2025-10-15 · Alkermes, Inc. · $11.95 · Open Payments source 2025-10-27 · Alkermes, Inc. · $12.13 · Open Payments source 2025-12-03 · Alkermes, Inc. · $25.97 · Open Payments source 2025-12-09 · Alkermes, Inc. · $7.00 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$286.13	22	2025
Source payment records 2025-01-06 · Alkermes, Inc. · $10.98 · Open Payments source 2025-01-22 · Alkermes, Inc. · $16.47 · Open Payments source 2025-02-21 · Alkermes, Inc. · $23.43 · Open Payments source 2025-03-12 · Alkermes, Inc. · $6.02 · Open Payments source 2025-03-12 · Alkermes, Inc. · $4.29 · Open Payments source 2025-04-17 · Alkermes, Inc. · $10.78 · Open Payments source 2025-04-28 · Alkermes, Inc. · $11.46 · Open Payments source 2025-05-19 · Alkermes, Inc. · $11.74 · Open Payments source 2025-05-29 · Alkermes, Inc. · $9.77 · Open Payments source 2025-06-11 · Alkermes, Inc. · $21.56 · Open Payments source 2025-06-18 · Alkermes, Inc. · $10.22 · Open Payments source 2025-06-21 · Alkermes, Inc. · $7.19 · Open Payments source 2025-07-10 · Alkermes, Inc. · $20.44 · Open Payments source 2025-07-23 · Alkermes, Inc. · $20.44 · Open Payments source 2025-08-04 · Alkermes, Inc. · $10.78 · Open Payments source 2025-09-03 · Alkermes, Inc. · $10.78 · Open Payments source 2025-09-12 · Alkermes, Inc. · $10.78 · Open Payments source 2025-10-01 · Alkermes, Inc. · $11.95 · Open Payments source 2025-10-15 · Alkermes, Inc. · $11.95 · Open Payments source 2025-10-27 · Alkermes, Inc. · $12.13 · Open Payments source 2025-12-03 · Alkermes, Inc. · $25.97 · Open Payments source 2025-12-09 · Alkermes, Inc. · $7.00 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$202.64	18	2025
Source payment records 2025-01-28 · Teva Pharmaceuticals USA, Inc. · $22.34 · Open Payments source 2025-05-07 · Teva Pharmaceuticals USA, Inc. · $10.70 · Open Payments source 2025-05-15 · Teva Pharmaceuticals USA, Inc. · $7.27 · Open Payments source 2025-05-15 · Teva Pharmaceuticals USA, Inc. · $32.58 · Open Payments source 2025-05-22 · Teva Pharmaceuticals USA, Inc. · $17.13 · Open Payments source 2025-06-19 · Teva Pharmaceuticals USA, Inc. · $2.17 · Open Payments source 2025-06-19 · Teva Pharmaceuticals USA, Inc. · $3.21 · Open Payments source 2025-06-19 · Teva Pharmaceuticals USA, Inc. · $3.82 · Open Payments source 2025-06-20 · Teva Pharmaceuticals USA, Inc. · $7.26 · Open Payments source 2025-07-10 · Teva Pharmaceuticals USA, Inc. · $5.21 · Open Payments source 2025-07-10 · Teva Pharmaceuticals USA, Inc. · $21.30 · Open Payments source 2025-08-05 · Teva Pharmaceuticals USA, Inc. · $5.80 · Open Payments source 2025-08-05 · Teva Pharmaceuticals USA, Inc. · $26.82 · Open Payments source 2025-08-27 · Teva Pharmaceuticals USA, Inc. · $4.18 · Open Payments source 2025-08-27 · Teva Pharmaceuticals USA, Inc. · $7.52 · Open Payments source 2025-09-15 · Teva Pharmaceuticals USA, Inc. · $7.14 · Open Payments source 2025-10-15 · Teva Pharmaceuticals USA, Inc. · $2.85 · Open Payments source 2025-10-15 · Teva Pharmaceuticals USA, Inc. · $15.34 · Open Payments source
Sunosi Normalized: sunosi	Drug	Axsome Therapeutics, Inc.	$158.57	7	2025
Source payment records 2025-05-13 · Axsome Therapeutics, Inc. · $27.68 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $20.76 · Open Payments source 2025-08-08 · Axsome Therapeutics, Inc. · $21.11 · Open Payments source 2025-08-08 · Axsome Therapeutics, Inc. · $5.96 · Open Payments source 2025-10-25 · Axsome Therapeutics, Inc. · $29.66 · Open Payments source 2025-11-19 · Axsome Therapeutics, Inc. · $28.11 · Open Payments source 2025-12-12 · Axsome Therapeutics, Inc. · $25.29 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$156.26	8	2025
Source payment records 2025-03-10 · Takeda Pharmaceuticals U.S.A., Inc. · $33.85 · Open Payments source 2025-04-07 · Takeda Pharmaceuticals U.S.A., Inc. · $18.20 · Open Payments source 2025-05-12 · Takeda Pharmaceuticals U.S.A., Inc. · $27.92 · Open Payments source 2025-06-26 · Takeda Pharmaceuticals U.S.A., Inc. · $2.96 · Open Payments source 2025-06-26 · Takeda Pharmaceuticals U.S.A., Inc. · $25.54 · Open Payments source 2025-10-17 · Takeda Pharmaceuticals U.S.A., Inc. · $3.06 · Open Payments source 2025-10-17 · Takeda Pharmaceuticals U.S.A., Inc. · $7.38 · Open Payments source 2025-11-12 · Takeda Pharmaceuticals U.S.A., Inc. · $37.35 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$146.03	11	2025
Source payment records 2025-01-22 · Tris Pharma Inc · $19.39 · Open Payments source 2025-02-06 · Tris Pharma Inc · $25.67 · Open Payments source 2025-02-20 · Tris Pharma Inc · $7.29 · Open Payments source 2025-02-21 · Tris Pharma Inc · $7.88 · Open Payments source 2025-03-13 · Tris Pharma Inc · $3.67 · Open Payments source 2025-03-24 · Tris Pharma Inc · $2.10 · Open Payments source 2025-03-24 · Tris Pharma Inc · $6.85 · Open Payments source 2025-07-12 · Tris Pharma Inc · $10.56 · Open Payments source 2025-12-03 · Tris Pharma Inc · $16.48 · Open Payments source 2025-12-04 · Tris Pharma Inc · $16.76 · Open Payments source 2025-12-11 · Tris Pharma Inc · $29.38 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$135.58	12	2025
Source payment records 2025-01-30 · Otsuka America Pharmaceutical, Inc. · $3.80 · Open Payments source 2025-02-04 · Otsuka America Pharmaceutical, Inc. · $4.90 · Open Payments source 2025-02-05 · Otsuka America Pharmaceutical, Inc. · $22.33 · Open Payments source 2025-02-28 · Otsuka America Pharmaceutical, Inc. · $7.53 · Open Payments source 2025-02-28 · Otsuka America Pharmaceutical, Inc. · $16.99 · Open Payments source 2025-03-01 · Otsuka America Pharmaceutical, Inc. · $7.88 · Open Payments source 2025-04-03 · Otsuka America Pharmaceutical, Inc. · $10.98 · Open Payments source 2025-04-04 · Otsuka America Pharmaceutical, Inc. · $2.79 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $2.22 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $22.44 · Open Payments source 2025-07-14 · Otsuka America Pharmaceutical, Inc. · $8.03 · Open Payments source 2025-08-16 · Otsuka America Pharmaceutical, Inc. · $25.69 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$135.58	12	2025
Source payment records 2025-01-30 · Otsuka America Pharmaceutical, Inc. · $3.80 · Open Payments source 2025-02-04 · Otsuka America Pharmaceutical, Inc. · $4.90 · Open Payments source 2025-02-05 · Otsuka America Pharmaceutical, Inc. · $22.33 · Open Payments source 2025-02-28 · Otsuka America Pharmaceutical, Inc. · $7.53 · Open Payments source 2025-02-28 · Otsuka America Pharmaceutical, Inc. · $16.99 · Open Payments source 2025-03-01 · Otsuka America Pharmaceutical, Inc. · $7.88 · Open Payments source 2025-04-03 · Otsuka America Pharmaceutical, Inc. · $10.98 · Open Payments source 2025-04-04 · Otsuka America Pharmaceutical, Inc. · $2.79 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $2.22 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $22.44 · Open Payments source 2025-07-14 · Otsuka America Pharmaceutical, Inc. · $8.03 · Open Payments source 2025-08-16 · Otsuka America Pharmaceutical, Inc. · $25.69 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$69.64	3	2025
Source payment records 2025-11-04 · Teva Pharmaceuticals USA, Inc. · $22.66 · Open Payments source 2025-11-12 · Teva Pharmaceuticals USA, Inc. · $17.30 · Open Payments source 2025-12-02 · Teva Pharmaceuticals USA, Inc. · $29.68 · Open Payments source
Quviviq Normalized: quviviq	Drug	IDORSIA PHARMACEUTICALS US INC	$20.08	1	2025
Source payment records 2025-04-24 · IDORSIA PHARMACEUTICALS US INC · $20.08 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$16.07	1	2025
Source payment records 2025-04-09 · Janssen Pharmaceuticals, Inc · $16.07 · Open Payments source
ZURZUVAE Normalized: zurzuvae	Drug	Biogen, Inc.	$14.39	1	2025
Source payment records 2025-06-10 · Biogen, Inc. · $14.39 · Open Payments source
INVEGA Normalized: invega	Drug	Janssen Pharmaceuticals, Inc	$14.34	1	2025
Source payment records 2025-01-10 · Janssen Pharmaceuticals, Inc · $14.34 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ABILIFY MAINTENA abilify maintena	2025	Abilify Maintena	2024	17 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	21 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
UZEDY uzedy	2025	Uzedy	2024	16 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	13 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	SPRAVATO open payments reported associated product	CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254	Spravato · 2024 Exact normalized brand match · 1 Part D row	18	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO open payments reported associated product	CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192	Austedo · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	UZEDY open payments reported associated product	CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226	Uzedy · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Clonazepam	Clonazepam	293	36
Alprazolam	Alprazolam	257	28
Aripiprazole	Aripiprazole	215	60
Trazodone Hcl	Trazodone Hcl	188	37
Lorazepam	Lorazepam	171	26
Gabapentin	Gabapentin	161	27
Lamotrigine	Lamotrigine	158	28
Bupropion Xl	Bupropion Hcl	153	33
Mirtazapine	Mirtazapine	123	27
Sertraline Hcl	Sertraline Hcl	114	25
Olanzapine	Olanzapine	100	28
Escitalopram Oxalate	Escitalopram Oxalate	91	18
Fluoxetine Hcl	Fluoxetine Hcl	89	24
Venlafaxine Hcl Er	Venlafaxine Hcl	89	16
Duloxetine Hcl	Duloxetine Hcl	85	18
Quetiapine Fumarate	Quetiapine Fumarate	79	16
Diazepam	Diazepam	76	11
Divalproex Sodium Er	Divalproex Sodium	73	16
Eszopiclone	Eszopiclone	62	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	61	12
Buspirone Hcl	Buspirone Hcl	60	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	58	11
Risperidone	Risperidone	37	suppressed
Prazosin Hcl	Prazosin Hcl	34	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	30	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Methadone Hcl	Methadone Hcl	25	suppressed
Propranolol Hcl	Propranolol Hcl	24	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Clozapine	Clozapine	21	suppressed
Modafinil	Modafinil	21	suppressed
Rexulti	Brexpiprazole	21	suppressed
Doxepin Hcl	Doxepin Hcl	19	suppressed
Haloperidol	Haloperidol	18	suppressed
Spravato	Esketamine Hcl	18	suppressed
Abilify Maintena	Aripiprazole	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Uzedy	Risperidone	16	suppressed
Armodafinil	Armodafinil	15	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	15	suppressed
Temazepam	Temazepam	15	suppressed
Vilazodone Hcl	Vilazodone Hcl	15	suppressed
Lithium Carbonate Er	Lithium Carbonate	14	suppressed
Oxcarbazepine	Oxcarbazepine	14	suppressed
Austedo	Deutetrabenazine	13	suppressed
Vraylar	Cariprazine Hcl	13	suppressed
Carisoprodol	Carisoprodol	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Lithium Carbonate	Lithium Carbonate	12	suppressed
Lurasidone Hcl	Lurasidone Hcl	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Trintellix	Vortioxetine Hydrobromide	12	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	12	suppressed
Belsomra	Suvorexant	11	suppressed
Caplyta	Lumateperone Tosylate	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$6,561.77 · 451 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, INGREZZA, INVEGA, INVEGA SUSTENNA, LYBALVI, Quviviq, REXULTI, Sunosi, TRINTELLIX, UZEDY, VRAYLAR, ZURZUVAE	11	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Abilify Maintena play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error